. 2023 Mar 7;16(1):133–159. doi: 10.1016/j.jcmgh.2023.03.001

Table 1.

Clinicopathological Correlation of FSP1 Overexpression in Human HCC

Clinicopathological phenotype	Number of cases	Mean	P-value
Cellular differentiation by Edmonson grading
I‒III	23	0.43	.101
IV‒VI	40	0.23
Chronic liver disease
Normal	12	0.25	.638
Chronic hepatitis and cirrhosis	53	0.32
Direct liver invasion
Absent	24	0.29	.726
Present	36	0.25
Hepatitis B surface antigen by IHC
Absent	16	0.25	.511
Present	44	0.34
Hepatitis C surface antigen by IHC
Absent	13	0.38	.018^a
Present	21	0.00
Plasma hepatitis B surface antigen
Absent	9	0.33	.718
Present	40	0.40
pTNM stage
I/II	30	0.30	.718
I/II/III/IV	32	0.34
Tumor encapsulation
Absent	27	0.41	.440
Present	17	0.53
Tumor microsatellite formation
Absent	25	0.36	.550
Present	35	0.29
Tumor size
≤ 5 cm	33	0.18	.021^a
> 5 cm	31	0.45
Venous invasion
Absent	19	0.47	.829
Present	25	0.44

Note: Mean: average values of FSP1 expression in human HCC samples relative to its paired NT tissues determined with the formula: ΔCt^{HCC(FSP1-18S)} – ΔCt^NT(FSP1-18S).

Note: Boldface P values indicate statistical significance.

FSP1, Ferroptosis suppressor protein 1; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; NT, non-tumorous; pTNM, pathological tumor-node-metastasis.

T test: P < .05.